Thera Neuropharma is focused on developing innovative therapeutic interventions for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Traumatic Brain Injury (TBI). The company employs two primary technologies: Small Molecule Regenerative Therapy (SMRT) and self-delivering RNA interference (sd-rxRNA®). The SMRT technology utilizes a dual-target approach that activates the nuclear factor - κB p65 subunit (NF-κB) and enhances the expression of manganese superoxide dismutase (MnSOD), which are crucial for neuronal function and survival. This approach aims to maintain brain cell viability and promote regeneration within the central nervous system, potentially leading to disease-modifying effects.

In addition to SMRT, Thera's sd-rxRNA® platform offers a gene-silencing mechanism that can inhibit the expression of specific proteins implicated in neurodegenerative processes. This technology is particularly focused on targeting the SOD1 gene, which is associated with ALS. The sd-rxRNA® oligonucleotides are designed to block the production of harmful proteins, thereby addressing the underlying pathogenic mechanisms of neurodegenerative diseases. Together, these technologies represent a multifaceted approach to treating complex disorders, with ongoing research and development aimed at optimizing lead candidates and expanding therapeutic applications to other neurological conditions.

United States

Thera Neuropharmainvestigates the use of small molecules and RNA-based compounds as therapeutics to treat Amyotrophic Lateral Sclerosis (ALS)andTraumatic Brain Injury (TBI).

Thera Neuropharma

Company Details